Breaking News Instant updates and real-time market news.

GE

General Electric

$9.45

-0.035 (-0.37%)

, X

U.S. Steel

$11.81

-0.4 (-3.28%)

07:30
06/03/19
06/03
07:30
06/03/19
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Friday in General Electric (GE), US Steel (X), Caesars (CZR), Bed Bath & Beyond (BBBY), CSX (CSX), Mattel (MAT), Murphy Oil (MUR), Finisar (FNSR), and Genesis Energy (GEL).

GE

General Electric

$9.45

-0.035 (-0.37%)

X

U.S. Steel

$11.81

-0.4 (-3.28%)

CZR

Caesars

$8.79

-0.275 (-3.03%)

BBBY

Bed Bath & Beyond

$12.69

-0.08 (-0.63%)

CSX

CSX

$74.47

-0.53 (-0.71%)

MAT

Mattel

$9.86

-0.75 (-7.07%)

MUR

Murphy Oil

$24.84

-0.05 (-0.20%)

FNSR

Acquired by IIVI

$20.99

-0.48 (-2.24%)

GEL

Genesis Energy

$21.85

-0.29 (-1.31%)

  • 05

    Jun

  • 12

    Jun

  • 24

    Jun

  • 13

    Nov

GE General Electric
$9.45

-0.035 (-0.37%)

06/03/19
JPMS
06/03/19
NO CHANGE
JPMS
Underweight
JPMorgan continues to see 'little support' for Moody's rating on GE
After Moody's issued an update to its credit rating on General Electric late Friday, JPMorgan analyst Stephen Tusa says he continues to see "little support" for the current rating. By the analyst's analysis of the numbers, things have not been "stable" at GE since Moody's downgrade seven months ago, nor is the company "showing steady progress versus what was expected in November of 2018." In a research note titled "Stable"?, Tusa also points out that GE and Moody's share a board member. He keeps an Underweight rating on shares of General Electric.
05/03/19
JPMS
05/03/19
NO CHANGE
JPMS
Overweight
GE may be putting money into GECS for 'many years to come,' says JPMorgan
General Electric's $1.9B insurance contribution this past quarter, and the resulting language around it, support the view that insurance is a "negative call" on capital and equity value, JPMorgan analyst Stephen Tusa tells investors in a research note titled "GECS Landlocked As Leverage Flattered By Restricted, Regulatory Capital." Further, the equity that is building in the segment is being "inappropriately double counted" as equity for the General Electric Capital Services shareholder, says the analyst. He models that GECS is worth zero and believes it is "becoming increasingly clear" how under-capitalized both GECS and GE Capital Aviation Services are. GE will likely need to contribute capital to these segments beyond the $4B expected in 2019, "potentially for many years to come," according to Tusa. The analyst views GE's capital requirement assumptions as "aggressive" and keeps an Underweight rating on the shares.
05/15/19
JPMS
05/15/19
NO CHANGE
JPMS
Underweight
GE managing Power headlines rather than fundamentals, says JPMorgan
General Electric's headline of 4.5 GWs in gas turbine orders promoted by management on the company's Q1 conference call in April was reaffirmed yesterday with the McCoy data on a headline basis, JPMorgan analyst Stephen Tusa tells investors in a research note. However, a closer look shows externally sold utility grade HDGT orders of ~1 GW, well below both Siemens and MHI and "far from a signal of a change in trend or upside versus our thesis," Tusa adds. The analyst still believes GE is losing market share in a "stable" HDGT market, especially in advanced class. The analyst believes yesterday's reporting is evidence of a "company that appears to manage to headlines rather than on-the-ground fundamentals." Tusa keeps an Underweight rating on shares of General Electric.
05/28/19
JPMS
05/28/19
NO CHANGE
JPMS
Underweight
GE Power bull case overlooks factors out of management control, says JPMorgan
The bull case on GE Power appears to factor in a combination of market recovery and internal execution, but the "stubbornly negative" macro and micro forces that are outside of management's control are being overlooked by investors, JPMorgan analyst Stephen Tusa tells investors in a research note. These include competition from existing players like MHI, Siemens and Ansaldo, who continue to develop new products, while emerging competition from China is coming, says Tusa. The analyst believes the consensus is banking on a GE Power recovery in 2021/2022. However, the acceleration of the introduction of new turbines from the Chinese "now looks to be firmly within that timeframe," according to Tusa. He keeps an Underweight rating on General Electric shares.
X U.S. Steel
$11.81

-0.4 (-3.28%)

05/06/19
BMOC
05/06/19
NO CHANGE
Target $17
BMOC
Market Perform
U.S. Steel price target lowered to $17 from $23 at BMO Capital
BMO Capital analyst David Gagliano lowered his price target on U.S. Steel to $17 and kept his Market Perform rating after the company disclosed a $1B Mon Valley Works investment along with its Q1 results. The analyst contends that the spending marks a "valuation overhang" for U.S. Steel shares amid the softer underlying market conditions and a challenging longer-term competitive environment, generating "little if any" free cash flow for the foreseeable future.
05/30/19
DBAB
05/30/19
DOWNGRADE
Target $11
DBAB
Sell
U.S. Steel downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded U.S. Steel to Sell from Hold and lowered his price target for the shares to $11 from $20. The analyst made rating changes in the Steel and Service Centers space after reviewing his firm's pricing forecasts. Terry says that even though stocks have been already been under pressure, he's cautious on the near term for the Steel and Service Centers sub-sector. The analyst moved his recommendations to a more negative stance and sees value elsewhere, especially in precious metals.
05/30/19
DBAB
05/30/19
DOWNGRADE
DBAB
Sell
U.S. Steel downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Nucor to Sell from Hold to reflect a more negative stance on steel.
05/08/19
UBSW
05/08/19
DOWNGRADE
Target $10
UBSW
Sell
U.S. Steel downgraded to Sell from Neutral at UBS
UBS analyst Andreas Bokkenheuser downgraded U.S. Steel to Sell from Neutral with a $10 price target.
CZR Caesars
$8.79

-0.275 (-3.03%)

05/29/19
DBAB
05/29/19
NO CHANGE
DBAB
Deutsche Bank sees increased odds of Eldorado, Caesars merger
Deutsche Bank analyst Carlo Santarelli believes the likelihood for an Eldorado Resorts (ERI) / Caesars Entertainment (CZR) pairing has increased and that the transaction would be a net positive for both companies as well as the gaming group. The analyst would be buyers of both stocks at current levels. Strengthening same-store fundamentals and continued M&A activity in the coming months should drive increased investor interest in the gaming group, Santarelli tells investors in a research note.
03/20/19
JPMS
03/20/19
NO CHANGE
Target $60
JPMS
Overweight
Eldorado shares could be worth $72-$80 with Caesars deal, says JPMorgan
JPMorgan analyst Daniel Politzer estimates that an Eldorado Resorts (ERI) acquisition of Caesars Entertainment (CZR) could generate $300M in synergies, imply a valuation of $72-$80 per share, and be ~50% accretive on a free cash flow per share basis. Reuters reported over the weekend that the two companies are in merger talks. The analyst's scenario contemplates Eldorado acquiring Caesars for $10.50 per share, or a 23% premium to last night's close, with the offer consisting of $6.25 in cash and $4.25 worth of stock. Politzer keeps an Overweight rating on Eldorado Resorts with a $60 price target.
01/18/19
MSCO
01/18/19
NO CHANGE
MSCO
Overweight
Morgan Stanley prefers Las Vegas to Macau in gaming entering 2019
Morgan Stanley analyst Thomas Allen said he is confident that the Las Vegas outlook is better than perceived after Q4 appears to have shown a meaningful rebound, noting also that his convention tracker supports strong 2019 demand growth and that flight capacity to the market is growing. Meanwhile, as a firm, Morgan Stanley has cut its Macau market gaming revenue outlook and industry view, Allen noted. Combining his Las Vegas outlook and bullish stance on regional U.S. gaming, Allen called MGM Resorts (MGM) and Caesars (CZR) his preferred large cap gaming stocks entering 2019, stating that he believes expectations for both are beatable. He reiterates Overweight ratings on both, as well as on Las Vegas Sands (LVS), and keeps an Equal Weight rating on Wynn Resorts (WYNN).
03/20/19
FBCO
03/20/19
INITIATION
Target $13
FBCO
Outperform
Caesars assumed with an Outperform at Credit Suisse
Credit Suisse analyst Ben Combes assumed coverage of Caesars with an Outperform rating and $13 price target.
BBBY Bed Bath & Beyond
$12.69

-0.08 (-0.63%)

04/11/19
MSCO
04/11/19
NO CHANGE
Target $20
MSCO
Equal Weight
Bed Bath's weak Q1 view calls FY19 guidance into question, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said he is skeptical Bed Bath & Beyond will be able to deliver results in line with its "overly optimistic" 2019 guidance given the company's weak Q1 outlook. He also questions the achievability of the company's "bullish" long-term guidance as he expects macroeconomic pressure and competitive headwinds to intensify. Gutman added that he believes Bed Bath's intention to accelerate its board refreshment process may not suffice and that the company could be headed towards a proxy fight with the activists that are involved in the stock. He keeps an Equal Weight rating and $20 price target on Bed Bath & Beyond shares.
04/11/19
UBSW
04/11/19
NO CHANGE
Target $18
UBSW
Neutral
Bed Bath & Beyond price target raised to $18 from $13 at UBS
UBS analyst Michael Lasser raised his price target on Bed Bath & Beyond to $18 after its Q4 earnings beat but also kept his Neutral rating, questioning the management's announced strategy update. The analyst cites the company's plans to "cut back on couponing, lower marketing spend, reduce store labor, and make returns more stringent" as running "counter to what most retailers are doing currently" as they aim to capture more customers. Lasser adds that prioritizing profitability over sales has a "limited shelf life", and its current planned actions will make its low-single-digit long term sales growth objective "hard to achieve".
04/11/19
DBAB
04/11/19
NO CHANGE
Target $19
DBAB
Hold
Bed Bath & Beyond price target raised to $19 from $15 at Deutsche Bank
Deutsche Bank analyst Mike Baker raised his price target for Bed Bath & Beyond to $19 from $15 following the company's "relatively in-line" quarter and guidance increase. The analyst keeps a Hold rating on the shares. The guidance is back-end weighted with the Q1 outlook weaker than expected, Baker tells investors in a research note. While bulls will focus on the presence of an activist investor and the long term transformational plan as two ways to win, bears will focus in on the fact that the shares have already had a significant move higher and that the initiatives put forth in the guidance are still largely unproven, contends the analyst. Baker sees "somewhat limited" share downside in the near term with activists likely to unveil their detailed operational plan in the next two weeks.
04/05/19
04/05/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Simeon Gutman saying he believes activist intervention presents the potential for upside for the stock in the near-term. 2. Snap (SNAP) upgraded to Hold from Sell at Summit Insights. 3. Northrop Grumman (NOC) upgraded to Positive from Neutral at Susquehanna. 4. Weyerhaeuser (WY) upgraded to Overweight from Equal Weight at Stephens with analyst Mark Connelly saying the stock, which is generally viewed as an income play, has sold off on rate concerns and slower starts. 5. Viacom (VIA, VIAB) upgraded to Outperform from Sector Perform at RBC Capital with analyst Steven Cahall saying the company's "less contentious" than feared DirecTV (T) deal improves its standing and "paves the way toward merger talks" with CBS (CBS). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CSX CSX
$74.47

-0.53 (-0.71%)

04/17/19
BMOC
04/17/19
NO CHANGE
Target $78
BMOC
Market Perform
CSX price target raised to $78 from $76 at BMO Capital
BMO Capital analyst Fadi Chamoun raised his price target on CSX to $78 after its "modestly better than expected" Q1 results, even when excluding "contribution from one-time items". The analyst notes that until now, CSX has been an "efficiency improvement with strong execution" story, but believes that "materially improved" service levels could generate volume growth and sustain the company's strong earnings momentum over the medium term. Chamoun is keeping his Market Perform rating on CSX stock to reflect its "balanced valuation" and his cautious macro view.
04/17/19
SBSH
04/17/19
NO CHANGE
Target $86
SBSH
Buy
CSX shares should move toward $86 as estimates rise, says Citi
Citi analyst Christian Wetherbee sees estimates moving higher and shares of CSX moving towards his $86 price target following the company's Q1 results. CSX's operating ratio improved sequentially "against typically strongly negative seasonality," leading to results which were "solidly better" than expected, Wetherbee tells investors in a post-earnings research note. He thinks the company's report will be viewed favorably across rails as a strong start to 2019. The analyst keeps a Buy rating on CSX.
04/17/19
FBCO
04/17/19
NO CHANGE
Target $93
FBCO
Outperform
CSX price target raised to $93 from $88 at Credit Suisse
Credit Suisse analyst Allison Landry raised her price target for CSX to $93 from $88, while reiterating an Outperform rating on the shares. While there were a couple of transitory items that helped in the quarter, the analyst believes they do not at all detract from the otherwise compelling long term story at CSX that the Q1 results are underwriting, namely that the company continues to execute on meaningful structural cost take-outs, a higher quality revenue stream, and improved free cash flow conversion.
04/05/19
UBSW
04/05/19
DOWNGRADE
Target $80
UBSW
Neutral
CSX downgraded to Neutral from Buy at UBS
UBS analyst Thomas Wadewitz downgraded CSX to Neutral from Buy while raising his price target for the shares to $80 from $75. The stock, after performing strongly on a multi-year basis and also in 2019, now reflects the good news in terms of further margin improvement and "industry leading" operating ratio performance, Wadewitz tells investors in a research note. The analyst believes CSX's reward/risk is no longer skewed to the upside at current share levels.
MAT Mattel
$9.86

-0.75 (-7.07%)

12/24/18
BMOC
12/24/18
NO CHANGE
Target $20
BMOC
Spin Master licensing deal with Warner negative for Mattel, says BMO Capital
BMO Capital analyst Gerrick Johnson says the Friday report of a DC superheroes licensing deal between Toys R Us Spin Master and Warner is a negative for Mattel. While the report has not been confirmed, the analyst believes that the business will be lost after 2019. Longer term, the analyst keeps his Outperform rating and $20 price target on Mattel and believes that its management "can facilitate needed changes in culture, product development, digital content, and partner relationships to drive sales and earnings growth."
02/08/19
MKMP
02/08/19
NO CHANGE
Target $15
MKMP
Neutral
Mattel price target raised to $15 from $12 at MKM Partners
MKM Partners analyst Eric Handler raised his price target on Mattel to $15 after its Q4 results surprised to the upside. The analyst also keeps his Neutral rating, noting that while the cost cuts have contributed to the earnings beat, the "revenue turnaround is still a work in progress".
02/26/19
BMOC
02/26/19
NO CHANGE
Target $20
BMOC
Outperform
Mattel price target lowered to $20 from $23 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Mattel to $20 after attending the company's Toy Fair analyst event. The analyst states that while he is "encouraged" by its efforts to reposition business toward profitable growth, the turnaround involving "SKU rationalization,process improvement, cost reduction, and infrastructure investments" could take longer than he anticipated. Longer term, Johnson keeps his Outperform rating on Mattel and believes that the stock still has "value that will continue to be unlocked" amid the management's transformation efforts.
10/26/18
JEFF
10/26/18
NO CHANGE
Target $13
JEFF
Hold
Jefferies says Mattel valuation 'still stretched,' cuts target to $13
At first glance, Mattel's earnings report "was in range," but unpacking the results uncovered a "more challenging set of facts" with sales down 10%, Jefferies analyst Stephanie Wissink tells investors in a post-earnings research note. She lowered her estimates for Mattel and dropped her price target for the shares to $13 from $14. The multiple at current share levels is " still stretched," says Wissink.
MUR Murphy Oil
$24.84

-0.05 (-0.20%)

04/12/19
GSCO
04/12/19
NO CHANGE
GSCO
Goldman downgrades California Resources, Chesapeake to Sell, upgrades Murphy
Within the Exploration and Production space, Goldman Sachs analyst Brian Singer recommends selling stocks where the valuation post recent rallies "appears at odds" with the company's competitive positioning. With that in mind, Singer downgraded both California Resources (CRC) and Chesapeake Energy (CHK) to Sell from Neutral. California Resources has a low decline rate and competitive supply cost but unfavorable debt cost that does not warrant the extent of its current valuation premium, says the analyst. For Chesapeake, Singer sees less favorable supply cost and corporate returns. The analyst also upgraded Murphy Oil (MUR) to Neutral from Sell. He believes the stock's current valuation appears more in line with its competitive positioning. Singer recommends buying "low cost oil suppliers" Encana (ECA), Parsley Energy (PE), Pioneer Natural (PXD) and EOG Resources (EOG) and Chevron (CVX).
04/12/19
04/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Martin Marietta (MLM) upgraded to Buy from Neutral at Goldman Sachs analyst Jerry Revich saying he is positive on an inflection in the aggregates pricing cycle, an acceleration in infrastructure capital expenditures, and potential return to a "steady recovery" for residential construction in 2020-2021. 2. Adient (ADNT) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy saying he believes Adient is in the process of refinancing its debt, despite investor concerns of a potential liquidity crunch, which would allow it to execute on its turnaround. 3. Exact Sciences (EXAS) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Patrick Donnelly citing his view that the stock is set-up well for the remainder of 2019. 4. Delphi Technologies (DLPH) upgraded to Buy from Neutral at BofA/Merrill with analyst John Murphy saying new CEO Rick Dauch's business review will come to a close in mid-April and expects more formal and constructive updates around Delphi's transformation plan. 5. Murphy Oil (MUR) upgraded to Neutral from Sell at Goldman Sachs with analyst John Murphy saying he believes Adient is in the process of refinancing its debt, despite investor concerns of a potential liquidity crunch, which would allow it to execute on its turnaround. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/30/19
EVER
05/30/19
INITIATION
Target $30
EVER
In Line
Murphy Oil initiated with an In Line at Evercore ISI
Evercore ISI started Murphy Oil with an In Line rating and $30 price target.
05/30/19
05/30/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. UroGen Pharma (URGN) initiated with a Neutral at JPMorgan. 2. Tecnoglass (TGLS) initiated with a Buy at DA Davidson. 3. Krystal Biotech (KRYS) initiated with a Buy at Guggenheim. 4. Huya (HUYA) initiated with a Buy at BofA/Merrill. 5. Murphy Oil (MUR) initiated with an In Line at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
FNSR Acquired by IIVI
$20.99

-0.48 (-2.24%)

03/01/19
PIPR
03/01/19
NO CHANGE
Target $24.5
PIPR
Overweight
Finisar revenue growth remains 'elusive,' says Piper Jaffray
Finisar last night reported December quarter results similar to last quarter with earnings upside but revenues below consensus, Piper Jaffray analyst Troy Jensen tells investors in a research note. The company made improvements in gross margins, but given greater than 70% of its sales are datacom related and the segment continues to see weakness, Jensen adds. As such, "solid revenue growth remains elusive," he says. The analyst maintains a Buy rating on Finisar shares with a $24.50 price target.
12/31/18
12/31/18
UPGRADE
Target $40

Outperform
II-VI upgraded to Outperform on valuation at Northland
As previously reported, Northland upgraded II-VI (IIVI) to Outperform from Market Perform and increased its price target to $40 from $39. Analyst Tim Savageaux said the pullback in shares following the Finisar (FNSR) discounts an overly negative view given both pro forma earnings power and deal synergies of nearly $4/share.
05/02/19
CHLM
05/02/19
NO CHANGE
Target $54
CHLM
Buy
II-VI price target raised to $54 from $47 at Craig-Hallum
Craig-Hallum analyst Richard Shannon raised his price target for II-VI (IIVI) to $54 from $47, assuming the company will close Finisar (FNSR) and based on his projected 2021 EPS for the combined entity. The analyst reiterates a Buy rating on II-VI shares.
05/01/19
PIPR
05/01/19
NO CHANGE
Target $50
PIPR
Overweight
II-VI Q3 results show 'strong optical demand', says Piper Jaffray
Piper Jaffray analyst Troy Jensen kept his Overweight rating and $50 price target on II-VI (IIVI) after its Q3 results, saying its Q3 earnings miss was driven by slower than expected 3D sensing revenue growth, even though the demand for its optical business remained strong. The analyst still believes that 3D sensing will be a tailwind for II-VI longer term and also sees its Finisar (FNSR) acquisition tracking according to plan toward a closing in 2-3 months.
GEL Genesis Energy
$21.85

-0.29 (-1.31%)

09/04/18
BARD
09/04/18
DOWNGRADE
BARD
Neutral
Genesis Energy downgraded to Neutral from Outperform at Baird
09/04/18
BARD
09/04/18
DOWNGRADE
Target $26
BARD
Neutral
Genesis Energy downgraded to Neutral at Baird
As reported previously, Baird analyst Ethan Bellamy downgraded Genesis Energy to Neutral from Outperform. The analyst noted the company shaved off some of its leverage ratio with the divestiture of its Powder River Basin property, but he believes the deleveraging pace has slowed and he doesn't expect a valuation move until the leverage recedes meaningfully in 2020. Bellamy maintained his $26 price target on Genesis Energy shares.
11/02/18
RBCM
11/02/18
UPGRADE
RBCM
Outperform
Genesis Energy upgraded to Outperform from Sector Perform at RBC Capital
11/02/18
RBCM
11/02/18
UPGRADE
Target $29
RBCM
Outperform
Genesis Energy upgraded to Outperform at RBC Capital on cash flow ramp
As reported earlier, RBC Capital analyst TJ Schultz upgraded Genesis Energy to Outperform from Sector Perform and raised his price target to $29 from $26. The analyst notes that Q3 has likely marked an inflection point in terms of generating onshore cash flow growth which coincided with the quarter's "moderate capex". Schultz adds that the combination allows Genesis Energy to "grow distributions, keep healthy coverage, and improve balance sheet".

TODAY'S FREE FLY STORIES

NSC

Norfolk Southern

$184.87

-3.98 (-2.11%)

, CSX

CSX

$72.19

-0.1 (-0.14%)

15:35
10/23/19
10/23
15:35
10/23/19
15:35
Downgrade
Norfolk Southern, CSX, Kansas City Southern, Union Pacific, Canadian National rating change  »

BofA downgrades Norfolk…

NSC

Norfolk Southern

$184.87

-3.98 (-2.11%)

CSX

CSX

$72.19

-0.1 (-0.14%)

KSU

Kansas City Southern

$146.06

1.02 (0.70%)

UNP

Union Pacific

$169.56

-1.26 (-0.74%)

CNI

Canadian National

$89.06

-0.8 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

  • 21

    Nov

  • 22

    Nov

LRCX

Lam Research

$231.75

-3.16 (-1.35%)

15:34
10/23/19
10/23
15:34
10/23/19
15:34
Options
Lam Research options imply 8.3% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

15:31
10/23/19
10/23
15:31
10/23/19
15:31
Conference/Events
Morgan Stanley oil/gas E&P analysts to hold an analyst/industry conference call »

Analysts, along with…

POAI

Predictive Oncology

$0.41

-0.01 (-2.38%)

15:25
10/23/19
10/23
15:25
10/23/19
15:25
Conference/Events
Predictive Oncology to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MU

Micron

$44.56

-0.12 (-0.27%)

15:23
10/23/19
10/23
15:23
10/23/19
15:23
Recommendations
Micron analyst commentary  »

Micron files annual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

  • 20

    Nov

NSC

Norfolk Southern

$184.63

-4.22 (-2.23%)

15:22
10/23/19
10/23
15:22
10/23/19
15:22
Downgrade
Norfolk Southern rating change  »

Norfolk Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

EBAY

eBay

$39.00

0.03 (0.08%)

15:19
10/23/19
10/23
15:19
10/23/19
15:19
Options
EBay options imply 8.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

GOGO

Gogo

$5.99

0.08 (1.35%)

15:18
10/23/19
10/23
15:18
10/23/19
15:18
Hot Stocks
Gogo AVANCE platform exceeds 175,000 business aviation flights »

Gogo Business Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 20

    Nov

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:18
10/23/19
10/23
15:18
10/23/19
15:18
Earnings
FirstService reports Q3 adjusted EPS 92c, consensus $1.03 »

Earlier, FirstService…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/23/19
10/23
15:17
10/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/23/19
10/23
15:16
10/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:15
10/23/19
10/23
15:15
10/23/19
15:15
Earnings
Correction: FirstService reports Q3 adjusted EPS 92c, consensus $1.03 »

Earlier, FirstService…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:13
10/23/19
10/23
15:13
10/23/19
15:13
Recommendations
FirstService analyst commentary  »

FirstService estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

15:12
10/23/19
10/23
15:12
10/23/19
15:12
Conference/Events
Morgan Stanley financial services analysts hold analyst/industry conference call »

Financial Analysts Cyprys…

MSFT

Microsoft

$136.19

-0.2 (-0.15%)

15:07
10/23/19
10/23
15:07
10/23/19
15:07
On The Fly
Fly Intel: What to watch in Microsoft earnings report »

Microsoft (MSFT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

XOM

Exxon Mobil

$69.49

0.38 (0.55%)

15:06
10/23/19
10/23
15:06
10/23/19
15:06
Hot Stocks
Qilak LNG executes heads of agreement with ExxonMobil for natural gas »

Qilak LNG, a Lloyds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XLNX

Xilinx

$93.83

-2.18 (-2.27%)

15:04
10/23/19
10/23
15:04
10/23/19
15:04
Options
Xilinx options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 20

    Nov

FTNW

FTE Networks

$1.15

0.28 (32.18%)

14:52
10/23/19
10/23
14:52
10/23/19
14:52
Hot Stocks
Breaking Hot Stocks news story on FTE Networks »

FTE Networks Inc trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$254.68

-0.94 (-0.37%)

14:49
10/23/19
10/23
14:49
10/23/19
14:49
Options
Tesla options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

KR

Kroger

$24.96

0.1 (0.40%)

14:45
10/23/19
10/23
14:45
10/23/19
14:45
Options
Kroger call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

14:45
10/23/19
10/23
14:45
10/23/19
14:45
General news
Treasury's $41 B 5-year auction was well supported »

Treasury's $41 B…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

, MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

14:38
10/23/19
10/23
14:38
10/23/19
14:38
Hot Stocks
FDA approves niraparib for HRD-positive advanced ovarian cancer »

On October 23, the Food…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 07

    Dec

TSLA

Tesla

$253.92

-1.7 (-0.67%)

14:27
10/23/19
10/23
14:27
10/23/19
14:27
On The Fly
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

14:25
10/23/19
10/23
14:25
10/23/19
14:25
Conference/Events
Senate Caucus on International Narcotics Control holds a hearing »

The Caucus holds a…

ALKS

Alkermes

$19.30

0.88 (4.78%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Recommendations
Alkermes analyst commentary  »

Alkermes making some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.